Free Trial
NASDAQ:REPL

Replimune Group Q3 2026 Earnings Results & Report

Replimune Group logo
$21.78 -1.50 (-6.44%)
Closing price 11/11/2026 04:00 PM Eastern
Extended Trading
$21.74 -0.04 (-0.16%)
As of 11/11/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Replimune Group beat analyst earnings expectations in its Q3 2026 results, released February 3, 2026. The company reported EPS of -$0.77 versus the -$0.85 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Replimune Group EPS Results

Actual EPS
-$0.77
Consensus EPS
-$0.85
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Replimune Group Revenue Results

Actual Revenue
N/A
Expected Revenue
$429 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Replimune Group Q3 2026 Earnings FAQ

Replimune Group (NASDAQ:REPL) reported earnings of -$0.77 per share for Q3 2026, beating the consensus estimate of -$0.85. The report was announced on Tuesday, February 3, 2026.

Replimune Group Earnings Headlines

Short Interest Powder Kegs: 10 Stocks Bears Cannot Quit Buying
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
Cramer's lightning round: Buy FedEx Freight
See More Replimune Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Replimune Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Replimune Group and other key companies, straight to your email.

About Replimune Group

Replimune Group (NASDAQ:REPL) is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer.

The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches. These programs remain investigational and are being evaluated in clinical studies.

Founded in 2015, Replimune is headquartered in Woburn, Massachusetts. Its work centers on research and clinical development rather than marketed products or services.

View Replimune Group Profile